Adaptive Biotechnologies ADPT EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Adaptive Biotechnologies’s reported figures.
Based on trailing twelve months.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's EBITDA margin?
- Adaptive Biotechnologies (ADPT) reported EBITDA margin of -10.1% in Q1 2026.
- How has Adaptive Biotechnologies's EBITDA margin changed year-over-year?
- Adaptive Biotechnologies's EBITDA margin increased by 84.7% year-over-year, from -65.8% to -10.1%.
- What is the long-term trend for Adaptive Biotechnologies's EBITDA margin?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's EBITDA margin has grown at a -37.3% compound annual growth rate (CAGR), from -146.7% to -14.2%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.